Literature DB >> 15717032

FDA: evidentiary standards for drug development and approval.

Russell Katz1.   

Abstract

The United States Food and Drug Administration is charged with approving drug treatments that have been shown to be safe and effective. Relevant statutes and regulations provide a legal framework for establishing safety and effectiveness that is sufficiently flexible to ensure that appropriate scientific data are collected for specific treatments targeted to particular diseases. Nonetheless, all clinical trials proposed to establish effectiveness must incorporate common elements in order for the appropriate legal and scientific standards of drug approval to be met. This article will discuss the relevant laws and regulations pertaining to the current effectiveness standard and will discuss the most important clinical trial design elements currently considered acceptable for applications for treatments of neurologic and psychiatric illness.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15717032      PMCID: PMC534930          DOI: 10.1602/neurorx.1.3.307

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  6 in total

1.  World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects.

Authors: 
Journal:  Bull World Health Organ       Date:  2003-07-02       Impact factor: 9.408

2.  Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 2: practical issues and specific cases.

Authors:  S S Ellenberg; R Temple
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

3.  Slowing the progression of Alzheimer disease: methodologic issues.

Authors:  P Leber
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

Review 4.  Surrogate end points in clinical trials: are we being misled?

Authors:  T R Fleming; D L DeMets
Journal:  Ann Intern Med       Date:  1996-10-01       Impact factor: 25.391

5.  Hazards of inference: the active control investigation.

Authors:  P D Leber
Journal:  Epilepsia       Date:  1989       Impact factor: 5.864

6.  Placebo-controlled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues.

Authors:  R Temple; S S Ellenberg
Journal:  Ann Intern Med       Date:  2000-09-19       Impact factor: 25.391

  6 in total
  25 in total

1.  Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff
Journal:  Neurobiol Aging       Date:  2012-04-13       Impact factor: 4.673

Review 2.  Widening the path and window of opportunity for FDA approval of non-vitamin K oral anticoagulant specific antidotes and reversal agents.

Authors:  Sunny Patel; Dylan Steen
Journal:  J Thromb Thrombolysis       Date:  2016-02       Impact factor: 2.300

3.  The Use of Published Clinical Study Reports to Support U.S. Food and Drug Administration Approval of Imaging Agents.

Authors:  Dwaine Rieves; Paula Jacobs
Journal:  J Nucl Med       Date:  2016-07-21       Impact factor: 10.057

Review 4.  The oxidative stress theory of disease: levels of evidence and epistemological aspects.

Authors:  Pietro Ghezzi; Vincent Jaquet; Fabrizio Marcucci; Harald H H W Schmidt
Journal:  Br J Pharmacol       Date:  2016-08-04       Impact factor: 8.739

5.  Achieving Informed Consent for Cellular Therapies: A Preclinical Translational Research Perspective on Regulations versus a Dose of Reality.

Authors:  Aileen J Anderson; Brian J Cummings
Journal:  J Law Med Ethics       Date:  2016-09       Impact factor: 1.718

Review 6.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices?

Authors:  Robert E Becker; Nigel H Greig; Ezio Giacobini
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

7.  Neuropsychiatric clinical trials: should they accommodate real-world practices or set standards for clinical practices?

Authors:  Robert E Becker; Nigel H Greig
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

Review 8.  Disease models for the development of therapies for lysosomal storage diseases.

Authors:  Miao Xu; Omid Motabar; Marc Ferrer; Juan J Marugan; Wei Zheng; Elizabeth A Ottinger
Journal:  Ann N Y Acad Sci       Date:  2016-05-04       Impact factor: 5.691

Review 9.  Alzheimer's disease drug development: old problems require new priorities.

Authors:  Robert E Becker; Nigel H Greig
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-12       Impact factor: 4.388

Review 10.  A new regulatory road-map for Alzheimer's disease drug development.

Authors:  Robert E Becker; Nigel H Greig
Journal:  Curr Alzheimer Res       Date:  2014-03       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.